title: Adverse skin reactions to infliximab in the treatment of intraocular inflammation.
abstract: TNFalpha inhibitors are more widely used in the treatment of intraocular inflammation, thus ophthalmologists should become aware of possible adverse events, associated with this form of treatment. Herein we report two cases of cutaneous adverse events in uveitis patients treated with infliximab. In one patient, the primary outbreak of pustular psoriasis was observed after her third infusion. A second patient developed impetigo contagiosa induced by Staphylococcus aureus. Thus patients undergoing treatment with infliximab should be monitored carefully since dermal infections and pustular psoriasis, which may be triggered by streptococcal infection, may occur under this regime.
authors.affiliation: Department of Ophthalmology, Medical University of Graz, Graz, Austria.
authors.forename: B J
authors.initials: BJ
authors.lastname: Wegscheider
authors.forename: L
authors.initials: L
authors.lastname: El-Shabrawi
authors.forename: M
authors.initials: M
authors.lastname: Weger
authors.forename: N
authors.initials: N
authors.lastname: Ardjomand
authors.forename: J
authors.initials: J
authors.lastname: Hermann
authors.forename: E
authors.initials: E
authors.lastname: Aberer
authors.forename: Y
authors.initials: Y
authors.lastname: El-Shabrawi
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007169:Impetigo / Q000139:chemically induced; D000069285:Infliximab; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab